Schering Plough's Saphris Gets Strong Nod From FDA Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
A safety profile showing less impact on weight and metabolic parameters than other atypical antipsychotics could set asenapine apart in crowded class if it is approved.
You may also be interested in...
Acorda's MS Drug Amaya Panel Review Leaves Little Time To React
The Peripheral and Central Nervous System Drugs Advisory Committee will review the mobility-enhancing drug one week before its scheduled PDUFA date.
Atypical Antipsychotic Market Snapshot: Making Way For Three New Drugs
Three newly-approved drugs - Schering Plough's Saphris, Johnson & Johnson's Invega Sustenna and Vanda's Fanapt - are poised to enter the atypical antipsychotic space despite the crowd of approved products and the specter of market genericization
Acorda's MS Drug Amaya Panel Review Leaves Little Time To React
The Peripheral and Central Nervous System Drugs Advisory Committee will review the mobility-enhancing drug one week before its scheduled PDUFA date.